Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

As Peers Fall To Jaw-dropping Valuations And Sell-off, India's Zydus Cadila Bets On JV To Co-exist

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - Large companies with well-oiled manufacturing skills and marketing networks in the growing Indian market have demonstrated their attractiveness as buyout targets for multinational companies, but analysts suggest that there could also be a significant interest developing from both sides of the spectrum in signing up proportionately profitable joint ventures for building strong manufacturing assets

You may also be interested in...



Backed By Biosimilars, Vaccines, Transdermals And Respiratory Drugs, India's Cadila Sets Sights On $3 Billion In Sales By 2015

Cadila is said to have allocated $20 million for its Vermont-headquartered unit Zydus Technologies to work on a range of compounds to be delivered via transdermal patches.

Backed By Biosimilars, Vaccines, Transdermals And Respiratory Drugs, India's Cadila Sets Sights On $3 Billion In Sales By 2015

Cadila is said to have allocated $20 million for its Vermont-headquartered unit Zydus Technologies to work on a range of compounds to be delivered via transdermal patches.

Backed By Biosimilars, Vaccines, Transdermals And Respiratory Drugs, India's Cadila Sets Sights On $3 Bil In Sales By 2015

AHMEDABAD, India - In a few months India's Zydus Cadila will join a handful of elite Indian companies like Dr. Reddy's and Cipla that managed to surpass the magic $1 billion mark in annual sales. Cadila says it has a comprehensive blueprint ready to cruise to $3 billion by 2015

Related Content

UsernamePublicRestriction

Register

SC075106

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel